Gene Delivery to Human Limbal Stem Cells Using Viral Vectors.


Journal

Human gene therapy
ISSN: 1557-7422
Titre abrégé: Hum Gene Ther
Pays: United States
ID NLM: 9008950

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 9 8 2019
medline: 28 3 2020
entrez: 9 8 2019
Statut: ppublish

Résumé

Limbal stem cell (LSC) transplantation is a promising treatment for ocular surface diseases especially LSC deficiency. Genetic engineering represents an attractive strategy to increase the potential for success in LSC transplantations either by correcting autologous diseased LSCs or by decreasing the immunogenicity of allogeneic LSCs. Therefore, two popular viral vectors, adeno-associated viral (AAV) vector and lentiviral (LV) vector, were compared for gene delivery in human LSCs. Transduction efficiency was evaluated by flow cytometry, quantitation of viral genomes, and fluorescence microscopy after introducing eight self-complementary AAV serotypes or LV carrying a green fluorescent protein (GFP) cassette to fresh limbal epithelial cells, cultivated LSC colonies, or after corneal intrastromal injection into human explant tissue. For fresh limbal epithelial cells, AAV6 showed the highest transduction efficiency, followed by LV and AAV4 at 24 h after vector incubation, which did not directly correlate with internalized genome copy number. The colony formation efficiency, as well as colony size over time, showed no significant differences among AAV serotypes, LV, and nontreated controls. The percentage of GFP+ colonies at 14 days post-seeding was significantly higher in the LV group, which plateaued at 50% GFP+ upon serial passages. Interestingly, AAV6-treated colonies initially showed a variegated transduction phenotype with no GFP+ colonies in serial passages. Quantitative polymerase chain reaction and AAV6 capsid staining revealed that transduction was restricted to differentiated cells of LSC colonies at a post-entry step. Following central intrastromal injection of human corneas, both LV and AAV6 transduced the stroma and endothelial cells, and AAV6 also transduced cells of the epithelia. However, no transduction was observed in derived LSC colonies. The collective results demonstrate the effectiveness of LV for stable human LSC genetic engineering and an unreported phenomenon of AAV6 transduction restriction in multipotent cells derived from the human limbus.

Identifiants

pubmed: 31392914
doi: 10.1089/hum.2019.071
pmc: PMC6939591
doi:

Substances chimiques

Green Fluorescent Proteins 147336-22-9

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1336-1348

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK058702
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI072176
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128119
Pays : United States
Organisme : NINDS NIH HHS
ID : P30 NS045892
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR064369
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL155986
Pays : United States

Références

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5279-86
pubmed: 18515566
Ont Health Technol Assess Ser. 2008;8(7):1-58
pubmed: 23074512
Nature. 2014 Jul 17;511(7509):353-7
pubmed: 25030174
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5125-9
pubmed: 14638707
Lancet. 2004 Dec 18-31;364(9452):2181-7
pubmed: 15610804
Exp Eye Res. 2005 Sep;81(3):247-64
pubmed: 16051216
Proc Natl Acad Sci U S A. 1984 Oct;81(20):6466-70
pubmed: 6093102
Gene Ther. 2018 Sep;25(6):402-414
pubmed: 30072815
Science. 1996 Apr 12;272(5259):263-7
pubmed: 8602510
Mol Vis. 2011;17:2102-17
pubmed: 21850186
N Engl J Med. 2010 Jul 8;363(2):147-55
pubmed: 20573916
Microbiol Spectr. 2015 Aug;3(4):null
pubmed: 26350320
Mol Ther. 2008 Dec;16(12):1968-76
pubmed: 18797449
Invest Ophthalmol Vis Sci. 2007 Jan;48(1):144-56
pubmed: 17197527
Clin Ophthalmol. 2019 Feb 18;13:383-390
pubmed: 30858688
J Biol Chem. 2015 Aug 14;290(33):20448-54
pubmed: 26045558
Curr Opin Ophthalmol. 2017 Jul;28(4):348-354
pubmed: 28399066
PLoS One. 2013;8(3):e58757
pubmed: 23516552
Stem Cells. 2005;23(1):63-73
pubmed: 15625123
Hum Gene Ther. 2017 Jun;28(6):450-463
pubmed: 28490211
Nature. 2017 Nov 16;551(7680):327-332
pubmed: 29144448
Nat Biotechnol. 2019 Mar;37(3):252-258
pubmed: 30778232
Sci Rep. 2017 Dec 19;7(1):17840
pubmed: 29259248
Arq Bras Oftalmol. 2010 Sep-Oct;73(5):447-53
pubmed: 21225131
J Biol Chem. 1984 Apr 10;259(7):4661-6
pubmed: 6323482
Virol J. 2013 Mar 06;10:74
pubmed: 23497173
Expert Opin Biol Ther. 2006 Apr;6(4):367-78
pubmed: 16548763
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61
pubmed: 11248048
Sci Rep. 2019 Mar 6;9(1):3631
pubmed: 30842485
Cornea. 2015 Nov;34(11):1478-86
pubmed: 26312622
PLoS One. 2011;6(11):e27520
pubmed: 22114676
Mol Vis. 2011;17:1652-61
pubmed: 21738394
Stem Cells Int. 2015;2015:601731
pubmed: 26146504
Retrovirology. 2011 Jun 24;8:51
pubmed: 21702950
Hum Gene Ther. 2018 Oct;29(10):1140-1152
pubmed: 30070149
Stem Cells. 2014 Apr;32(4):938-45
pubmed: 24170316

Auteurs

Liujiang Song (L)

Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina.

Zhenwei Song (Z)

Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina.

Nathaniel J Fry (NJ)

Department of Microbiology, University of North Carolina, Chapel Hill, North Carolina.

Laura Conatser (L)

Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina.

Telmo Llanga (T)

Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina.

Hua Mei (H)

Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina.

Tal Kafri (T)

Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina.
Department of Microbiology, University of North Carolina, Chapel Hill, North Carolina.

Matthew L Hirsch (ML)

Gene Therapy Center, University of North Carolina, Chapel Hill, North Carolina.
Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH